NCT00407589

Systemic Pharmacokinetics of BOL-303224-A

Systemic Pharmacokinetics of BOL-303224-A After Single and Multiple Instillations of BOL-303224-A in Subjects With Suspected Bacterial Conjunctivitis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, open-label, single dose/multiple dose, pharmacokinetic study in participants with bacterial conjunctivitis. The purpose of this study is to determine the extent of systemic exposure to BOL-303224-A following single and multiple topical administration of BOL-303224-A in participants with suspected bacterial conjunctivitis.

Conditions

• Conjunctivitis, Bacterial

Interventions

Type	Name	Description
DRUG	BOL-303224-A	1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).

Timeline

• Start date: 2006-10-01
• Primary completion: 2007-10-01
• Completion: 2007-10-01
• First posted: 2006-12-05
• Last updated: 2011-12-09

Locations

1 site across 1 country: United States